CoChat

Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report

Open access
McGuire, Helen M., Shklovskaya, Elena, Edwards, Jarem, Trevillian, Paul R., McCaughan, Geoffrey W., Bertolino, Patrick, McKenzie, Catriona, Gourlay, Ralph, Gallagher, Stuart J., Fazekas de St. Groth, Barbara, Hersey, Peter · 2018 · Cancer Immunology, Immunotherapy
Cited by 63

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Effective treatment or prevention of immune side effects associated with checkpoint inhibitor therapy of cancer is an important goal in this new era of immunotherapy. Hepatitis due to immunotherapy with antibodies against PD-1 is uncommon and generally of low severity. We present an unusually severe case arising in a melanoma patient after more than 6 months uncomplicated treatment with anti-PD-1 in an adjuvant setting. The hepatitis rapidly developed resistance to high-dose steroids, requiring anti-thymocyte globulin (ATG) to achieve control. Mass cytometry allowed comprehensive phenotyping of circulating lymphocytes and revealed that CD4 + T cells were profoundly depleted by ATG, while CD8 + T cells, B cells, NK cells and monocytes were relatively spared. Multiple abnormalities in CD4 + T cell phenotype were stably present in the patient before disease onset. These included a population of CCR4 − CCR6 − effector/memory CD4 + T cells expressing intermediate levels of the Th1-related chemokine receptor CXCR3 and abnormally high multi-drug resistance type 1 transporter (MDR1) activity as assessed by a rhodamine 123 excretion assay. Expression of MDR1 has been implicated in steroid resistance and may have contributed to the severity and lack of a sustained steroid response in this patient. The number of CD4 + rhodamine 123-excreting cells was reduced > 3.5-fold after steroid and ATG treatment. This case illustrates the need to consider this form of steroid resistance in patients failing treatment with corticosteroids. It also highlights the need for both better identification of patients at risk and the development of treatments that involve more specific immune suppression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00262-017-2107-7

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 63

Metadata

Authors
McGuire, H. M., Shklovskaya, E., Edwards, J., Trevillian, P. R., McCaughan, G. W., Bertolino, P., McKenzie, C., Gourlay, R., Gallagher, S. J., Fazekas de St. Groth, B., & Hersey, P.
Venue
Cancer Immunology, Immunotherapy
Published
2017-12-30
Volume
67
Issue
4
Pages
563-573
ISSN
  • 0340-7004 (ISSN-L)
  • 1432-0851
OpenAlex
W2778761730
Cited by
63
References
9
FWCI
3.23
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. https://app.cochat.ai/papers/10.1007/s00262-017-2107-7
The paper
McGuire, H. M., Shklovskaya, E., Edwards, J., Trevillian, P. R., McCaughan, G. W., Bertolino, P., McKenzie, C., Gourlay, R., Gallagher, S. J., Fazekas de St. Groth, B., & Hersey, P. (2018). Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-017-2107-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.